- Home
- ACET vs CATO Comparison
ACET vs CATO Comparison
Compare ACET & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- CATO
- Stock Information
- Founded
- ACET 1947
- CATO 1946
- Country
- ACET United States
- CATO United States
- Employees
- ACET N/A
- CATO N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- CATO Clothing/Shoe/Accessory Stores
- Sector
- ACET Health Care
- CATO Consumer Discretionary
- Exchange
- ACET Nasdaq
- CATO Nasdaq
- Market Cap
- ACET 61.2M
- CATO 59.2M
- IPO Year
- ACET N/A
- CATO N/A
- Fundamental
- Price
- ACET $0.76
- CATO $2.81
- Analyst Decision
- ACET Buy
- CATO
- Analyst Count
- ACET 6
- CATO 0
- Target Price
- ACET $6.00
- CATO N/A
- AVG Volume (30 Days)
- ACET 406.7K
- CATO 34.4K
- Earning Date
- ACET 08-12-2025
- CATO 08-21-2025
- Dividend Yield
- ACET N/A
- CATO 6.05%
- EPS Growth
- ACET N/A
- CATO N/A
- EPS
- ACET N/A
- CATO N/A
- Revenue
- ACET N/A
- CATO $642,949,000.00
- Revenue This Year
- ACET N/A
- CATO N/A
- Revenue Next Year
- ACET N/A
- CATO N/A
- P/E Ratio
- ACET N/A
- CATO N/A
- Revenue Growth
- ACET N/A
- CATO N/A
- 52 Week Low
- ACET $0.45
- CATO $2.19
- 52 Week High
- ACET $1.70
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- ACET 57.89
- CATO 46.89
- Support Level
- ACET $0.58
- CATO $2.79
- Resistance Level
- ACET $0.82
- CATO $3.07
- Average True Range (ATR)
- ACET 0.04
- CATO 0.18
- MACD
- ACET 0.01
- CATO -0.02
- Stochastic Oscillator
- ACET 74.79
- CATO 16.67
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.